NNEPI Home Page About NNEPI Online Course Info Advisory Board Frequently Asked Questions Site Map Contact Us
 
Hospital-based Nursing
Hospice & Home Health Nurses
School Nurses
Public Health Nurses
Nursing Home and Assited Living Facility Nurses
Occupational Nurses
Ambulatory Care Nurses

Buy Lamivudine (Epivir, Epivir-HBV) tablets online


How and where to order Epivir, Epivir-HBV (Lamivudine) 100 mg, 150 mg tablets online:

Shop:DFH PHARMACY
Sellers:LAMIVUDINE STORES
Prices:from $0.78 per pill
Discount:10% coupon: DFH10
Forms:Lamivudine 100 mg, 150 mg tablets
Quantity:10-360 pills
Type:Lamivudine brand, Epivir generic, Epivir-HBV generic
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Regular airmail and express courier
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Epivir

Indications and usage:

  • Epivir (Lamivudine) is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
  • Limitations of use: the dosage of this product is for HIV-1 and not for HBV.


    Dosage and administration:

  • Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily.
  • Pediatric patients aged 3 months and older: administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily.
  • Patients with renal impairment: doses of Epivir must be adjusted in accordance with renal function.


    Dosage forms and strengths:

  • Epivir (Lamivudine) scored tablets 150 mg.
  • Tablets 300 mg.
  • Oral solution: 10 mg per mL.


    Overdosage:

    There is no known specific treatment for overdose with Lamivudine (Epivir) tablets. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.


    Contraindications:

    Epivir is contraindicated in patients with previous hypersensitivity reaction to lamivudine.


    Warnings and precautions:

  • Co-infected HIV-1/HBV patients: emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported.
  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues.
  • Pancreatitis: use with caution in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Discontinue treatment as clinically appropriate.
  • Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy.
  • Lower virologic suppression rates and increased risk of viral resistance were observed in pediatric subjects who received Epivir oral solution concomitantly with other antiretroviral oral solutions compared with those who received tablets. An all-tablet regimen should be used when possible.


    Side effects, adverse reactions:

  • The most common reported adverse reactions (incidence greater than or equal to 15%) of lamivudine in adults were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough.
  • The most common reported adverse reactions (incidence greater than or equal to 15%) in pediatric subjects were fever and cough.
  • To report suspected adverse reactions of Epivir (Lamivudine) tablets and oral solution, contact GlaxoSmithKline, ViiV Healthcare pharmaceutical companies or your local FDA.


    Drug interactions:

    Sorbitol: coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration.

    Related medications:

  • Efavirenz, Emtricitabine, Tenofovir Disoproxil (Atripla)
  • Emtricitabine, Tenofovir Disoproxil (Truvada)


    Use in specific populations:

  • Pregnancy: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Epivir during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) in the USA at 1-800-258-4263.
  • Lactation: women infected with HIV should be instructed not to breastfeed due to potential for HIV transmission.


    Epivir-HBV

    Indications and usage:

    Epivir-HBV (Lamivudine) is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation.


    Dosage and administration:

  • Adults: 100 mg, once daily.
  • Pediatric patients aged 2 to 17 years: 3 mg per kg once daily up to 100 mg once daily. Prescribe oral solution for pediatric patients requiring less than 100 mg daily.
  • Patients with renal impairment: doses of Epivir-HBV must be adjusted in accordance with renal function.
  • This medication should not be used with other medications that contain lamivudine or emtricitabine.


    Dosage forms and strengths:

  • Epivir-HBV (Lamivudine) tablets 300 mg and oral solution 5 mg per ml.


    Overdosage:

    There is no known specific treatment for overdose with Epivir-HBV. If overdose occurs, the patient should be monitored and standard supportive treatment applied, as required. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.


    Contraindications:

    Epivir-HBV is contraindicated in patients with previous hypersensitivity reaction to lamivudine.


    Warnings and precautions:

  • Emergence of resistance-associated HBV substitutions: consider a switch to an alternative regimen if serum HBV DNA remains detectable after 24 weeks of treatment.
  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues.


    Side effects, adverse reactions:

  • The most common reported adverse reactions in those receiving Epivir-HBV (incidence greater than or equal to 10% and reported at a rate greater than placebo) were ear, nose, and throat infections; sore throat; and diarrhea.
  • To report suspected adverse reactions of Epivir-HBV (Lamivudine) tablets and oral solution, contact GlaxoSmithKline pharmaceutical company or your local FDA.


    Drug interactions:

    Sorbitol: coadministration of lamivudine and sorbitol may result in decreased lamivudine concentrations; when possible, avoid chronic coadministration. Consider more frequent monitoring of HBV viral load when chronic coadministration cannot be avoided.


    Use in specific populations:

  • Pregnancy: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) in the USA at 1-800-258-4263.
  • Lactation: the developmental and health benefits of breastfeeding should be considered along with the motherís clinical need for Epivir-HBV and any potential adverse effects on the breastfed infant from lamivudine or from the underlying maternal condition.


    Where to buy lamivudine online:

    To purchase Epivir-HBV, Epivir (Lamivudine) 100 mg, 150 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.


    Here is a list of popular medications containing lamivudine as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    3TC
  • Solution; Oral; Lamivudine 10 mg / ml
  • Tablets; Oral; Lamivudine 150 mg
  • Tablets; Oral; Lamivudine 300 mg
  • GlaxoSmithKline
  • ViiV Healthcare
  • Epivir
  • Solution; Oral; Lamivudine 10 mg / ml
  • Tablets, Film-Coated; Oral; Lamivudine 150 mg
  • Tablets, Film-Coated; Oral; Lamivudine 300 mg
  • GlaxoSmithKline
  • ViiV Healthcare
  • Epivir-HBV
  • Solution; Oral; Lamivudine 5 mg / ml
  • Tablets; Oral; Lamivudine 100 mg
  • GlaxoSmithKline
  • Shire
  • Lamivir
  • Syrup; Oral; Lamivudine 10 mg / ml
  • Tablets, Film-Coated; Oral; Lamivudine 150 mg
  • Tablets, Film-Coated; Oral; Lamivudine 300 mg
  • Cipla
  • Lamivir HBV
  • Tablets; Oral; Lamivudine 100 mg
  • Cipla



  • Copyright © 2005 - 2022 The National Nurse Emergency Preparedness Initiative (NNEPI). All Rights Reserved.